The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could lead to a positive short-term impact on Cytokinetics' stock price. The specific mention of a $108 price target suggests a significant upside potential from current levels, further underlining the positive outlook.